Arcus Biosciences RCUS anti-CD39 — Royalty expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:RoyaltyExpense.
The official record: Arcus Biosciences’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's anti-cd39 — royalty expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcus Biosciences's anti-cd39 — royalty expense?
- Arcus Biosciences (RCUS) reported anti-cd39 — royalty expense of $0 in Q4 2025.
- What does anti-cd39 — royalty expense mean?
- This metric represents the ongoing costs paid to third-party licensors or partners based on the commercial success or sales of anti-CD39 products. It reflects the long-term financial obligation associated with the intellectual property rights used in the development and sale of the therapy. Higher royalty expenses generally indicate successful commercialization but also represent a recurring reduction in net product margins.